B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIN3B

MOLECULAR TARGET

glutamate ionotropic receptor NMDA type subunit 3B

UniProt: Q8VHN2NCBI Gene: 17079615 compounds

GRIN3B (glutamate ionotropic receptor NMDA type subunit 3B) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIN3B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Glutamic Acid3.1823
2Glutamic Acid3.1823
3Glycine2.087
4pentamidine1.795
5Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of1.614
6Levorphanol1.614
7cycloserine1.393
8Aspartic Acid1.102
9Ethidium1.102
10D-Aspartic Acid0.691
11Dextrorphan Dextro form of levorphanol. It acts as0.691
12Dextrothyroxine0.691
13Dizocilpine Maleate0.691
14Ibotenic Acid0.691
15Spermine0.691

About GRIN3B as a Drug Target

GRIN3B (glutamate ionotropic receptor NMDA type subunit 3B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented GRIN3B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIN3B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.